Placebo vs Amoxicillin for Nonsevere Fast-Breathing Pneumonia in Malawian Children Aged 2 to 59 Months

Authors:

Abstract
Approximately 920 000 children die of pneumonia annually before their fifth birthday.1 There is a critical need to provide greater access to appropriate and effective treatment. Treatment of bacterial pneumonia requires an effective antibiotic used in adequate doses for an appropriate duration. A 3-day course of twice-daily amoxicillin is recommended by the World Health Organization (WHO) as first-line treatment of nonsevere fast-breathing pneumonia among immune-competent children aged 5 years or less.2 The WHO’s integrated management of childhood illness (IMCI) guidelines identify fast-breathing pneumonia in children with cough or difficult breathing who demonstrate fast breathing without WHO danger signs.3 However, not all cases of fast breathing are bacterial pneumonia. Indeed, the majority of fast-breathing pneumonia cases are likely not pneumonia at all. There are many reasons that a child might demonstrate fast breathing, and not all indicate disease.4-7 Thus, isolated fast breathing may not be appropriately sensitive nor specific for diagnosing pneumonia,8 making antibiotic treatment unnecessary. Although it is relatively well tolerated among children, amoxicillin has side effects and causes serious but rare adverse events.9 Furthermore, inappropriate antibiotic use may lead to antibiotic resistance.10-15

This publication has 27 references indexed in Scilit: